title: Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
authors.forename: A
authors.initials: A
authors.lastname: Kuendgen
authors.forename: R
authors.initials: R
authors.lastname: Fenk
authors.forename: I
authors.initials: I
authors.lastname: Bruns
authors.forename: M
authors.initials: M
authors.lastname: Dommach
authors.forename: A
authors.initials: A
authors.lastname: Schutte
authors.forename: R
authors.initials: R
authors.lastname: Engers
authors.forename: A
authors.initials: A
authors.lastname: Hünerlitürkoglu
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
mesh_terms: D000328:Adult; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012307:Risk Factors; D012422:Rupture, Spontaneous; D013161:Splenic Rupture / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim